The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis.
J. Chiu
No relevant relationships to disclose
Y. F. Tang
No relevant relationships to disclose
T. J. Yao
No relevant relationships to disclose
A. Wong
No relevant relationships to disclose
H. Wong
No relevant relationships to disclose
R. C. Leung
No relevant relationships to disclose
P. Chan
No relevant relationships to disclose
T. T. Cheung
No relevant relationships to disclose
R. T. P. Poon
Consultant or Advisory Role - Bayer Schering Pharma (B,U)
S. T. Fan
No relevant relationships to disclose
C. C. Yau
Consultant or Advisory Role - Bayer Schering Pharma (U)